Other News

ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

PARIS–(BUSINESS WIRE)–Regulatory News: “ACTISAVE Clinical Trial: Efficacy and Safety of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy.” Post this ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including stroke, announces the presentation, […]

HRS 2024: Vektor Medical’s vMap Technology to be Highlighted in Rhythm Theater and Eight Posters

SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today unveiled a comprehensive schedule of educational content and sessions featuring the use of vMap® at this year’s Heart Rhythm 2024 conference in Boston, May 16-19. vMap rapidly provides actionable arrhythmia localization insights for physicians. The research and presentations at HRS […]

BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected

LONDON–(BUSINESS WIRE)–BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI. Novel target for Heart Failure was discovered using BenevolentAI’s AI-drug […]

Simpson Interventions Accepted into FDA’s TAP Pilot Program for Breakthrough Device, Acolyte™ Catheter System

CAMPBELL, Calif.–(BUSINESS WIRE)–Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced its acceptance into the Total Product Life Cycle Advisory Program Pilot (TAP Pilot) by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). “This acknowledgment underscores […]

HeartFlow’s Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study

MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its REVEALPLAQUE study, highlighting the accuracy of its Plaque Analysis, was published in the European Heart Journal Cardiovascular Imaging.